Kevin Kalinsky

Has grant

Emory University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Validation of Low Ovarian Functional Reserve as an Indicator of Chemotherapy Benefit

Open Date: 2024-10-01

Close Date: 2025-09-30

Grant: Close

Biomarker Assessment in Patients with Node-Positive Breast Cancer

Open Date: 2022-10-01

Close Date: 2023-09-30

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (8)

Prabhjot Mundi

Assistant Professor

Columbia University Irving Medical Center

UNITED STATES

View details

Meghna Trivedi

Assistant Professor

Columbia University Irving Medical Center

UNITED STATES

View details

KYONG HWA PARK

Associate Professor

Seoul National University Hospital

SOUTH KOREA

View details

Codruta (Cody) Chiuzan

Associate Professor

Northwell Health Feinstein Institutes for Medical Research

UNITED STATES

View details

Katherine Crew

Associate Professor

Columbia University Irving Medical Center

UNITED STATES

View details

Véronique Dieras

Head Breast Group

FRANCE

View details

Sarah Sammons

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES

View details

Giampaolo Bianchini

Head Breast Cancer Group

IRCCS Ospedale San Raffaele

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kevin Kalinsky

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (10)

Use of a Smartphone Application to Promote Adherence to Oral Medications in Patients With Breast Cancer

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer

Comprehensive Molecular and Genomic Analysis of NCI-MATCH Subprotocol Y: Capivasertib in Patients With an AKT1 E17K –Mutated Tumor

Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial

Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer

The Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life

Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression

Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial

Collaborators (8)

Prabhjot Mundi

Meghna Trivedi

KYONG HWA PARK

Codruta (Cody) Chiuzan

Katherine Crew

Véronique Dieras

Sarah Sammons

Giampaolo Bianchini

Make your next move.